Sanford C. Bernstein Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock

Key Points

• Sanford C. Bernstein raised its Zimmer Biomet price target from $93 to $107 but maintained a “market perform” rating; the new target implies only 0.26% upside from the share price cited in the report.
• Analyst sentiment is broadly neutral: the stock has an average “Hold” rating and an average price target of $107.63, with seven Buy, 16 Hold and one Sell rating.
• Zimmer Biomet’s latest quarterly results topped estimates, with EPS of $1.90 and revenue of $2.06 billion, up 3.1% year over year; the company also raised its full-year outlook. Shares fell 3.1% on Thursday.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective boosted by research analysts at Sanford C. Bernstein from $93.00 to $107.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a "market perform" rating on the medical equipment provider's stock. Sanford C. Bernstein's price target would indicate a potential upside of 0.26% from the company's current price.

A number of other research firms have also recently issued reports on ZBH. Canaccord Genuity Group lifted their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a "hold" rating in a research note on Monday, August 10th. Stifel Nicolaus set a $125.00 price objective on Zimmer Biomet in a report on Wednesday. UBS Group reissued a "buy" rating and set a $120.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Jefferies Financial Group restated a "hold" rating and set a $120.00 price objective on shares of Zimmer Biomet in a research report on Wednesday. Finally, Zacks Research raised shares of Zimmer Biomet from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 25th. Seven analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $107.63.

Zimmer Biomet Stock Down 3.1%

NYSE ZBH traded down $3.43 on Thursday, reaching $106.72. 1,277,847 shares of the stock traded hands, compared to its average volume of 2,253,712. The company has a market cap of $20.36 billion, a price-to-earnings ratio of 25.94, a PEG ratio of 2.33 and a beta of 0.50. The company has a fifty day moving average price of $94.90 and a 200-day moving average price of $91.89. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $112.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same period in the previous year, the company earned $1.90 earnings per share. The business's revenue for the quarter was up 3.1% on a year-over-year basis. As a group, research analysts forecast that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by corporate insiders.

Institutional Trading of Zimmer Biomet

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Zimmer Biomet in the 2nd quarter worth $1,344,282,000. Primecap Management Co. CA bought a new position in Zimmer Biomet during the 2nd quarter valued at about $328,578,000. Bank of America Corp DE bought a new stake in shares of Zimmer Biomet during the second quarter worth $187,480,000. Equity Investment Corp purchased a new position in Zimmer Biomet during the 2nd quarter worth $144,748,000. Finally, Legal & General Group Plc bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $126,167,000. 88.89% of the stock is currently owned by institutional investors.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, and adjusted diluted EPS of $1.90 beat analysts’ expectations. The company also raised its full-year 2026 outlook. Strong hip and S.E.T. sales helped offset softness in knees. Zimmer Biomet Announces Third Quarter 2026 Financial Results Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
• Positive Sentiment: Wells Fargo raised its price target to $113 from $103, while keeping an “equal weight” rating. Wells Fargo stock recommendations
• Neutral Sentiment: Management said it does not see a slowdown in orthopedic procedures, offering reassurance about underlying demand. Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
• Negative Sentiment: Adjusted EPS was unchanged from a year earlier, while reported diluted EPS fell 13.8% to $1.00. Knee-market weakness and margin pressure remain concerns despite growth in other product categories. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.